Skip to main content

Advertisement

SpringerLink
Log in

Nestin expression in brain tumors: its utility for pathological diagnosis and correlation with the prognosis of high-grade gliomas

  • Original Article
  • Published:
Brain Tumor Pathology Aims and scope Submit manuscript

Abstract

One of the type VI intermediate filament proteins, nestin, is expressed in neuroepithelial stem cells during neural embryogenesis. Nestin is also expressed in a variety of neoplasms. Its expression in brain tumors has not been thoroughly studied. The objectives of this study were to survey nestin expression in different types of brain tumor, and to evaluate nestin as a marker for diagnosis and prognosis. We used tissue microarrays of 257 brain tumors for an immunohistochemical overview of nestin expression: nestin was frequently expressed in gliomas and schwannomas. Most of the gliomas that expressed high levels of nestin were high-grade gliomas (anaplastic astrocytomas, anaplastic oligodendrogliomas, anaplastic oligoastrocytomas, and glioblastomas). We then focused on high-grade gliomas and performed immunohistochemistry again, using whole-mount slides. As a result, we found (1) significantly different nestin expression between glioblastomas and other high-grade gliomas, and (2) worse overall survival for high-grade gliomas with high nestin expression. Our results suggest that: (1) nestin is a useful marker for diagnosis of high-grade gliomas, (2) nestin is helpful in diagnosis of schwannomas, and (3) nestin expression is related to poor prognosis in high-grade gliomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Colin C, Virard I, Baeza N et al (2007) Relevance of combinatorial profiles of intermediate filaments and transcription factors for glioma histogenesis. Neuropathol Appl Neurobiol 33:431–439

    Article  PubMed  CAS  Google Scholar 

  2. Gu H, Wang S, Messam CA et al (2002) Distribution of nestin immunoreactivity in the normal adult human forebrain. Brain Res 943:174–180

    Article  PubMed  CAS  Google Scholar 

  3. Johansson CB, Momma S, Clarke DL et al (1999) Identification of a neural stem cell in the adult mammalian central nervous system. Cell 96:25–34

    Article  PubMed  CAS  Google Scholar 

  4. Tohyama T, Lee VM, Rorke LB et al (1992) Nestin expression in embryonic human neuroepithelium and in human neuroepithelial tumor cells. Lab Invest 66:303–313

    PubMed  CAS  Google Scholar 

  5. Tsujimura T, Makiishi-Shimobayashi C, Lundkvist J et al (2001) Expression of the intermediate filament nestin in gastrointestinal stromal tumors and interstitial cells of Cajal. Am J Pathol 158:817–823

    Article  PubMed  CAS  Google Scholar 

  6. Carrière C, Seeley ES, Goetze T et al (2007) The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia. Proc Natl Acad Sci USA 104:4437–4442

    Article  PubMed  Google Scholar 

  7. Flørenes VA, Holm R, Myklebost O et al (1994) Expression of the neuroectodermal intermediate filament nestin in human melanomas. Cancer Res 54:354–356

    PubMed  Google Scholar 

  8. Kleeberger W, Bova GS, Nielsen ME et al (2007) Roles for the stem cell associated intermediate filament nestin in prostate cancer migration and metastasis. Cancer Res 67:9199–9206

    Article  PubMed  CAS  Google Scholar 

  9. Li H, Cherukuri P, Li N et al (2007) Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res 67:501–510

    Article  PubMed  CAS  Google Scholar 

  10. Dahlstrand J, Collins VP, Lendahl U et al (1992) Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res 52:5334–5341

    PubMed  CAS  Google Scholar 

  11. Smits A, van Grieken D, Hartman M et al (1996) Coexpression of platelet-derived growth factor alpha and beta receptors on medulloblastomas and other primitive neuroectodermal tumors is consistent with an immature stem cell and neuronal derivation. Lab Invest 74:188–198

    PubMed  CAS  Google Scholar 

  12. You H, Kim YI, Im SY et al (2005) Immunohistochemical study of central neurocytoma, subependymoma, and subependymal giant cell astrocytoma. J Neurooncol 74:1–8

    Article  PubMed  Google Scholar 

  13. Kim BJ, Kim SS, Kim YI et al (2004) Forskolin promotes astroglial differentiation of human central neurocytoma cells. Exp Mol Med 36:52–56

    PubMed  CAS  Google Scholar 

  14. Ma YH, Mentlein R, Knerlich F et al (2008) Expression of stem cell markers in human astrocytomas of different WHO grades. J Neurooncol 86:31–45

    Article  PubMed  Google Scholar 

  15. Ikota H, Kinjo S, Yokoo H et al (2006) Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology. Acta Neuropathol 111:475–482

    Article  PubMed  CAS  Google Scholar 

  16. Nakazato Y, Ishizeki J, Takahashi K et al (1982) Localization of S-100 protein and glial fibrillary acidic protein-related antigen in pleomorphic adenoma of the salivary glands. Lab Invest 46:621–626

    PubMed  CAS  Google Scholar 

  17. Louis DN, Ohgaki H, Wiestler OD et al (2007) WHO classification of tumours of the central nervous system. IARC, Lyon

    Google Scholar 

  18. Strojnik T, Røsland GV, Sakariassen PO et al (2007) Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. Surg Neurol 68:133–143

    Article  PubMed  Google Scholar 

  19. Sarlomo-Rikala M, Tsujimura T, Lendahl U et al (2002) Patterns of nestin and other intermediate filament expression distinguish between gastrointestinal stromal tumors, leiomyomas and schwannomas. APMIS 110:499–507

    Article  PubMed  CAS  Google Scholar 

  20. Shimada S, Tsuzuki T, Kuroda M et al (2007) Nestin expression as a new marker in malignant peripheral nerve sheath tumors. Pathol Int 57:60–67

    Article  PubMed  CAS  Google Scholar 

  21. Yokoo H, Nobusawa S, Takebayashi H et al (2004) Anti-human Olig2 antibody as a useful immunohistochemical marker of normal oligodendrocytes and gliomas. Am J Pathol 164:1717–1725

    Article  PubMed  CAS  Google Scholar 

  22. Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773

    Article  PubMed  CAS  Google Scholar 

  23. Ichimura K, Pearson DM, Kocialkowski S et al (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11:341–347

    Article  PubMed  CAS  Google Scholar 

  24. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149–1153

    Article  PubMed  CAS  Google Scholar 

  25. Nobusawa S, Watanabe T, Kleihues P et al (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15:6002–6007

    Article  PubMed  CAS  Google Scholar 

  26. Hartmann C, Hentschel B, Wick W et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707–718

    Article  PubMed  Google Scholar 

  27. Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469–474

    Article  PubMed  Google Scholar 

  28. Capper D, Weissert S, Balss J et al (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245–254

    Article  PubMed  CAS  Google Scholar 

  29. Ikota H, Nobusawa S, Tanaka Y et al (2011) High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein. Brain Tumor Pathol 28:107–214

    Article  PubMed  CAS  Google Scholar 

  30. Nigro JM, Baker SJ, Preisinger AC et al (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705–708

    Article  PubMed  CAS  Google Scholar 

  31. Wong AJ, Bigner SH, Bigner DD et al (1987) Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84:6899–6903

    Article  PubMed  CAS  Google Scholar 

  32. Ishiwata T, Teduka K, Yamamoto T et al (2011) Neuroepithelial stem cell marker nestin regulates the migration, invasion and growth of human gliomas. Oncol Rep 26:91–99

    PubMed  CAS  Google Scholar 

  33. Piras F, Perra MT, Murtas D et al (2010) The stem cell marker nestin predicts poor prognosis in human melanoma. Oncol Rep 23:17–24

    PubMed  Google Scholar 

  34. Tanabe K, Amoh Y, Kanoh M et al (2010) Prognostic significance of the hair follicle stem cell marker nestin in patients with malignant melanoma. Eur J Dermatol 20:283–288

    PubMed  Google Scholar 

  35. Zhang M, Song T, Yang L et al (2008) Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res 27:85. doi:10.1186/1756-9966-27-85

  36. Chinnaiyan P, Wang M, Rojiani AM et al (2008) The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group. Radiat Oncol 3:32. doi:10.1186/1748-717X-3-32

  37. Kim KJ, Lee KH, Kim HS et al (2011) The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas. Neuropathology 31:494–502

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Human Pathology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan

    Hideo Arai, Hayato Ikota, Sumihito Nobusawa & Yoichi Nakazato

  2. Department of Neurosurgery, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan

    Ken-ichi Sugawara

  3. Department of Pathology, Gunma University Hospital, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan

    Hideo Arai & Junko Hirato

Authors
  1. Hideo Arai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hayato Ikota
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ken-ichi Sugawara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sumihito Nobusawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Junko Hirato
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoichi Nakazato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideo Arai.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arai, H., Ikota, H., Sugawara, Ki. et al. Nestin expression in brain tumors: its utility for pathological diagnosis and correlation with the prognosis of high-grade gliomas. Brain Tumor Pathol 29, 160–167 (2012). https://doi.org/10.1007/s10014-012-0081-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10014-012-0081-5

Keywords

Search

Navigation